Suven Life Sciences Limited has informed the Exchange regarding a press release dated August 16, 2021, titled "Suven Life sciences announces Phase 3 Clinical Trial of SUVN-502 (Masupirdine), a 5-HT6 antagonist for treatment of Agitation and aggression in Alzheimer s type dementias".